The Role of Proline Rich Tyrosine Kinase 2 (Pyk2) on Cisplatin Resistance in Hepatocellular Carcinoma

Abstract

Aims We previously demonstrated Proline rich tyrosine kinase 2 (Pyk2) plays important roles in regulating tumor progression, migration and invasion in hepatocellular carcinoma (HCC). In this study, we aimed to examine the role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in HCC and to explore its underlying molecular mechanism.Methodology/Principal FindingsStable transfectants either overexpressing or suppressing Pyk2 were established in different HCC cell lines. MTT, colony formation and Annexin-V assays were employed to examine their in vitro responses to cisplatin. Xenograft ectopic and orthotopic nude mice models were generated to investigate the in vivo responses of them to cisplatin treatment. cDNA microarray was performed to identify Pyk2-induced genes which were further validated by quantitative real-time RT-PCR using clinical HCC samples. In vitro functional study demonstrated that Pyk2-overexpressing HCC transfectants exhibited relatively lower cytotoxicity, higher colony-forming ability and lower apoptosis to cisplatin compared with the control transfectants. Moreover, Pyk2 overexpressing HCC transfectants had a higher survival rate under cisplatin treatment by up-regulation of AKT phosphorylation. In vivo xenograft nude mice model demonstrated that Pyk2-overexpressing transfectants developed higher tolerance to cisplatin treatment together with less tumor necrosis and apoptosis. cDNA microarray analysis revealed that there were more than 4,000 genes differentially expressed upon overexpression of Pyk2. Several upregulated genes were found to be involved in drug resistance and invasion in cancers. Among them, the expression profiles of MDR1, GAGE1, STAT1 and MAP7 were significantly associated with the expression of Pyk2 in clinical HCC samples.ConclusionsOur results may suggest a new evidence of Pyk2 on promoting cisplatin resistance of HCC cells through preventing cell apoptosis, activation of AKT pathway and upregulation of drug resistant genes.

Identification of Transmembrane Protein 98 as a Novel Chemoresistance-Conferring Gene in Hepatocellular Carcinoma

“…Genes involved in tumorigenesis have been also found to contribute to chemoresistance of hepatocellular carcinoma (13,15,22,23). Identification of hepatocellular carcinoma-associated targets is thus critical not only for understanding the molecular mechanisms of both intrinsic and acquired chemoresistance but also for developing hepatocellular carcinoma-associated targeted therapy.…”

Vasohibin 2 Decreases the Cisplatin Sensitivity of Hepatocarcinoma Cell Line by Downregulating p53

“…Apart from surgical treatment, systematic chemotherapy plays an important role in HCC treatment especially for patients with advanced HCC [32]. Currently, chemotherapy is ineffective for HCC treatment because of the inherent chemoresistance.…”

Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model

“…After fixation, the tumor was sliced in the central transverse section with a slice thickness of 2 mm to match IVIM images. Then hematoxylin eosin (HE) staining was performed on 3 μm sections for measuring the necrotic fraction (NF) of the tumor . The measurement was done by a pathologist with 7 years of experience in histologic analysis using an Olympus microscope (Olympus CKX41, Japan) at 200× magnification with software Image‐Pro Plus 6.1 at five randomly selected FOVs and the results were averaged .…”